Morgan Stanley ups Pharvaris to overweight, citing HAE drug prospects (NASDAQ:PHVS)


upgrade keyboard concept illustration


Morgan Stanley has upgraded Pharvaris (NASDAQ:PHVS) to overweight, citing growing confidence in the safety and efficacy profile of the company’s drug candidate deucrictibant in the treatment of hereditary angioedema.

The investment bank said it believes Pharvaris is positioned to be

Source link

Leave A Reply

Your email address will not be published.